CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 279 enrolled
Drug / intervention
PRESERFLO® MicroShunt +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04333433
NCT04333433N/ACompleted

A Prospective, Concurrent Controlled, Open-Label, Multicenter Clinical Study to Assess the Long-Term Safety of the PRESERFLO® MicroShunt in Subjects With Primary Open-Angle Glaucoma Who Have Completed Participation in the INN-005 Randomized Controlled Study.

InnFocus Inc.·observational·Posted Apr 3, 2020·Updated Mar 22, 2024

In Brief

An observational study evaluating PRESERFLO® MicroShunt and Trabeculectomy for Primary Open-angle Glaucoma. Completed, enrolled 279 participants across 23 sites in 5 countries.

Detailed Summary

This prospective, concurrent controlled, open-label, multicenter study is designed to collect additional safety data through 5 years of follow-up for subjects randomized to either the treatment arm (PRESERFLO® MicroShunt with MMC) or the control arm (Trabeculectomy with MMC) of the INN-005 clinical study.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesFrance, Italy, Spain, United Kingdom, United States
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedApr 3, 2020
Enrollment StartMay 22, 2020
Primary CompletionNov 24, 2022
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 6.2 years ago

Interventions

PRESERFLO® MicroShuntdevice

Device surgically implanted

Trabeculectomyprocedure

The procedure involves removal of a small portion of the trabecular meshwork and adjacent scleral tissue. Aqueous humor then drains into the subconjunctival space, creating a bleb on the external part of the eye, where it diffuses away.